title: Radical radiation therapy for adenocarcinoma of the uterine cervix.
abstract: OBJECTIVE
  Analysis of the therapeutic value of radical irradiation for patients with uterine cervical adenocarcinoma with special reference to pelvic disease control.
  
  
  METHODS
  20 patients with uterine cervical adenocarcinoma were treated with a combination of external beam and intracavitary irradiation (four patients stage IB, one stage IIA, three stage IIB and twelve patients stage IIIB). Seven patients were treated with high dose-rate (HDR) intracavitary irradiation, eleven with low dose-rate (LDR) intracavitary irradiation and two with HDR and LDR.
  
  
  RESULTS
  Six out of the 20 patients experienced pelvic recurrence (all stage IIIB patients). Analysis of the relation between pelvic recurrence and dose rate of intracavitary irradiation revealed that LDR showed a higher pelvic disease control rate than HDR (6/7 vs. 0/4) in stage IIIB patients. Intracavitary irradiation doses of LDR were 1.2 to 1.5 times higher than those of HDR. Three out of the 20 patients developed rectal complication grade 2 (two patients treated with HDR, one with LDR). The five-year cumulative survival rate was 67.2% for all, 100% for stage I and II, and 43.3% for stage IIIB patients.
  
  
  CONCLUSIONS
  These results suggest that locally advanced uterine cervical adenocarcinoma should be treated with a higher dose using LDR intracavitary irradiation. If adequate total doses can be delivered, pelvic disease control of uterine cervical adenocarcinoma is comparable with that achieved for squamous cell carcinoma.
authors.affiliation: Department of Radiology, University of the Ryukyus School of Medicine, Okinawa, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Toita
authors.forename: Y
authors.initials: Y
authors.lastname: Takizawa
authors.forename: M
authors.initials: M
authors.lastname: Nakano
authors.forename: H
authors.initials: H
authors.lastname: Sueyama
authors.forename: A
authors.initials: A
authors.lastname: Kushi
authors.forename: Y
authors.initials: Y
authors.lastname: Kakihana
authors.forename: K
authors.initials: K
authors.lastname: Ogawa
authors.forename: R
authors.initials: R
authors.lastname: Hara
authors.forename: M
authors.initials: M
authors.lastname: Higashi
authors.forename: K
authors.initials: K
authors.lastname: Sakumoto
mesh_terms: D000230:Adenocarcinoma / Q000150:complications / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D000328:Adult; D000368:Aged; D001918:Brachytherapy; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D009367:Neoplasm Staging; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D016019:Survival Analysis; D002583:Uterine Cervical Neoplasms / Q000150:complications / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*